Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases

A total of 109 patients with myelodysplastic syndromes (MDS) was analyzed to determine the clinical and pathologic features of the five recently defined French‐American‐British Cooperative Group (FAB) subtypes, and to assess the utility of this classification system in predicting survival, evolution...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1985-08, Vol.56 (3), p.553-561
Main Authors: Foucar, Kathy, Langdon, Robert M., Armitage, James O., Olson, Daniel B., Carroll, Thomas J.
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Applied sciences
Biological and medical sciences
Biopsy
Bone Marrow - pathology
Bone Marrow Transplantation
Combined Modality Therapy
Exact sciences and technology
Female
Hematologic and hematopoietic diseases
Humans
Leukemia - drug therapy
Leukemia - pathology
Leukemia, Myeloid - pathology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Other techniques and industries
Preleukemia - drug therapy
Preleukemia - pathology
Prognosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A total of 109 patients with myelodysplastic syndromes (MDS) was analyzed to determine the clinical and pathologic features of the five recently defined French‐American‐British Cooperative Group (FAB) subtypes, and to assess the utility of this classification system in predicting survival, evolution to acute nonlymphocytic leukemia (ANLL), and cause of death. All patients with MDS presented with anemia; additional cytopenias were present in patients with refractory anemia with excess blasts (RAEB), chronic myelomonocytic leukemia (CMML) and refractory anemia with excess blasts in transformation to ANLL (RAEB/Tr). Thirty‐two patients received some form of antileukemic therapy for MDS. ANLL developed in 16 of the 77 remaining untreated patients, including 18% (2/11), 0% (0/21), 22% (5/23), 33% (2/6), and 44% (7/16) of patients with refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), RAEB, CMML, and RAEB/Tr, respectively (P = 0.02). The FAB subtype was highly predictive of survival with median survivals ranging from 71 months for RARS to 5 months for RAEB/Tr (P =
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q